Fidasimtamab

• CAT Number: I042103
• CAS Number: 2377419-89-9
• Purity: ≥95%

Fidasimtamab（Cat No.:I042103）is an investigational monoclonal antibody targeting the immune checkpoint receptor TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains). TIGIT plays a role in suppressing immune responses, particularly in cancer. By inhibiting TIGIT, Fidasimtamab aims to enhance the body’s immune system, allowing T-cells to better attack cancer cells. It is being studied in clinical trials for the treatment of various cancers, including solid tumors. Early research suggests that Fidasimtamab may improve anti-tumor immunity, and further studies are underway to assess its safety and efficacy in cancer therapies.